RayKnowChina Research Map
Shortlist

RecruitingPancreatic cancerPhase 2

Registered title, quoted from ClinicalTrials.gov

Clinical Study of TQB2868 Injection Combined With Anlotinib Capsule and Chemotherapy in the First-line Treatment of Metastatic Pancreatic Neoplasms

An open trial on pancreatic cancer, registered on ClinicalTrials.gov. The lead sponsor is not a hospital on this site; 5 hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 5

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Study siteFirst Affiliated Hospital of Soochow University苏州大学附属第一医院SuzhouHospital page
  2. Study siteFirst Affiliated Hospital of Wenzhou Medical University温州医科大学附属第一医院WenzhouHospital page
  3. Study siteFudan University Shanghai Cancer Center复旦大学附属肿瘤医院ShanghaiHospital page
  4. Study siteHenan Cancer Hospital河南省肿瘤医院ZhengzhouHospital page
  5. Study siteNanjing Drum Tower Hospital南京鼓楼医院NanjingHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT06767813, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 7

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (7 points)Hide the checklist
  1. 18 years to 75 years; sex: all

    Registered eligibility fields

  2. Diagnosed with pancreatic ductal adenocarcinoma through histological or cytological confirmation.

    Inclusion criterion 3

  3. No prior systemic anti-tumor therapy (including but not limited to chemotherapy, radiotherapy, targeted therapy, or immunotherapy). Patients who experience disease progression more than 6 months after completing neoadjuvant or adjuvant therapy are eligible.

    Inclusion criterion 5

    Unresolved toxicities from prior treatments exceeding Grade 1 according to Common Terminology Criteria (CTC) AE criteria, excluding alopecia.

    Exclusion criterion 2

  4. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1, with an expected survival of more than 3 months.

    Inclusion criterion 6

  5. Have at least one evaluable metastatic lesion according to RECIST 1.1 criteria;

    Inclusion criterion 4

  6. Subjects with a history of or concurrent diagnosis of other malignant tumors within the past 5 years.

    Exclusion criterion 1

  7. Patients must use reliable contraception during the study period and for 6 months after the end of the study period; Female participants must have a negative serum or urine pregnancy test within 7 days prior to enrollment and must not be breastfeeding.

    Inclusion criterion 8

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: stage or severity, as the trial defines it; blood tests: counts, liver and kidney function.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT06767813, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • Subjects must voluntarily participate in the study and sign the informed consent form.
  • Aged between 18 and 75 years (inclusive) at the time of signing the informed consent form.
  • Diagnosed with pancreatic ductal adenocarcinoma through histological or cytological confirmation.
  • Have at least one evaluable metastatic lesion according to RECIST 1.1 criteria;
  • No prior systemic anti-tumor therapy (including but not limited to chemotherapy, radiotherapy, targeted therapy, or immunotherapy). Patients who experience disease progression more than 6 months after completing neoadjuvant or adjuvant therapy are eligible.
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0-1, with an expected survival of more than 3 months.
  • Normal major organ function.
  • Patients must use reliable contraception during the study period and for 6 months after the end of the study period; Female participants must have a negative serum or urine pregnancy test within 7 days prior to enrollment and must not be breastfeeding.

Exclusion Criteria:

  • Subjects with a history of or concurrent diagnosis of other malignant tumors within the past 5 years.
  • Unresolved toxicities from prior treatments exceeding Grade 1 according to Common Terminology Criteria (CTC) AE criteria, excluding alopecia.
  • Major surgical procedures, significant traumatic injuries, or unhealed wounds or fractures within 28 days prior to the first dose.
  • Any bleeding or hemorrhagic event of ≥ Grade 3 according to CTC AE criteria within 4 weeks prior to the first dose.
  • Arterial or venous thrombotic events within 6 months prior to the first dose.
  • Active gastric or duodenal ulcers, perforations, persistent positive fecal occult blood tests, ulcerative colitis, or other gastrointestinal bleeding conditions within 6 months prior to the first dose; or other bleeding conditions as assessed by the investigator.
  • Hepatitis B virus (HBV)-infected patients unable to adhere to consistent antiviral therapy, or Hepatitis C virus (HCV)-infected patients (positive for HCV Ab or HCV RNA) deemed unstable by the investigator or requiring continued antiviral therapy without consistent adherence.
  • History of substance abuse involving psychotropic drugs that cannot be discontinued or presence of psychiatric disorders.
  • Symptomatic interstitial lung disease or conditions likely to cause drug-induced lung toxicity or related pneumonitis.
  • Presence of any severe and/or uncontrolled diseases.
  • Histological or cytological confirmation of other pathological types, such as acinar cell carcinoma, neuroendocrine carcinoma, or pancreatoblastoma.
  • Tumors confirmed via imaging (CT or MRI) to have invaded major blood vessels, with the investigator deeming a high likelihood of fatal hemorrhage during the study.
  • Tumors confirmed via imaging (CT or MRI) to have invaded the gastrointestinal tract, with a high risk of bleeding based on endoscopy and investigator assessment.
  • Known central nervous system metastases and/or carcinomatous meningitis.
  • Uncontrolled pleural effusion, pericardial effusion, or ascites requiring repeated drainage, as assessed by the investigator.
  • History of severe allergic reactions to biologic agents or known hypersensitivity to any component of TQB2868 injection.
  • Chronic treatment with systemic corticosteroids or other immunosuppressive agents within 28 days prior to the first dose, and continued use of such medications within 2 weeks after the first dose.
  • Receipt of live attenuated vaccines within 28 days prior to the first dose or planned administration of live attenuated vaccines during the study.
  • Systemic therapy required within 2 years prior to the first dose for any condition. Alternative therapies are not considered systemic therapy.
  • Participation in other clinical trials involving anti-tumor drugs within 28 days prior to the first dose.
  • Any comorbidities or conditions deemed by the investigator to pose severe risks to the subject's safety or the completion of the study, or any other reasons rendering the subject unsuitable for enrollment.

Quoted from ClinicalTrials.gov, NCT06767813, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT06767813, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT06767813